Abstract

Objectives:This study aimed to investigate the predictive value of cardiac cycle time-corrected electromechanical activation time (EMATc) for major adverse cardiovascular events (MACEs) in outpatients with chronic heart failure (CHF) in comparison with other clinic indexes.Methods:This prospective observational study at Beijing Anzhen Hospital from January 01, 2015 to January 01 2018 enrolled 120 CHF patients who were admitted for acute onset of CHF and followed up after discharge for 616.5 days (range: 202.75–875.25 days). Based on the different endpoints, cardiogenic death, all-cause death, and HF-related readmission, patients were assigned to the following groups: cardiogenic death and non-cardiogenic death groups, all-cause death and survival groups, and HF readmission and non-readmission groups. EMATc and other clinic indexes were measured and compared between these groups. Cox regression analysis was used to identify independent risk factors for MACEs.Results:The hazard ratio for EMATc>15% for cardiogenic death was 3.493 (P=0.046), suggesting that an EMATc>15% was an independent risk factor for cardiogenic death in CHF patients. The hazard ratios for B-type natriuretic peptide (BNP) >400 ng/L for all-cause death and CHF readmission were 3.810 (P=0.008) and 2.764 (P=0.031), respectively. Thus, BNP >400 ng/L was an independent risk factor for all-cause death and readmission for CHF. EF<40% was not found to be a significant risk factor for MACEs.Conclusions:BNP level can predict the risk for poor prognosis in CHF patients. EMATc>15% is an independent risk factor for cardiogenic death and should be considered as a supplement to serum BNP level and other clinical indexes for predicting cardiogenic death in CHF outpatients.

Highlights

  • Chronic heart failure (CHF) is the end stage of a variety of cardiovascular diseases

  • Cardiac cycle time-corrected electromechanical activation time greater than 15% is an independent risk factor for major adverse cardiovascular events in chronic heart failure outpatients

  • Searching for predictors of poor prognosis in chronic heart failure (CHF) patients has been an active area of research

Read more

Summary

Introduction

Chronic heart failure (CHF) is the end stage of a variety of cardiovascular diseases. The high CHF mortality is mainly attributed to complications of cardiovascular etiology.[1] Despite medical advances, the all-cause mortality of CHF is 17%, and the readmission rate is 44%.2. Searching for predictors of poor prognosis in CHF patients has been an active area of research. Natriuretic peptides such as B-type natriuretic peptide (BNP) have been shown to have diagnostic and predictive value for CHF,[3] and left ventricular. Pak J Med Sci March - April 2022 Vol 38 No 3 www.pjms.org.pk 456 ejection fraction (EF) is the most commonly used prognostic indicator for CHF.[4] for stable CHF patients, repeated monitoring of BNP and echocardiography require considerable medical resources and increases the burden on society and the patients’ families.[5]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call